High Evidence
Research Overview
Survodutide Research for Type 2 Diabetes
An evidence-based overview of research examining Survodutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 RCT (N=413) demonstrated dose-dependent HbA1c reduction up to 1.71% at 16 weeks, comparable to open-label semaglutide 1mg (1.47%) at matched lower doses. Weight loss reached 8.7%, exceeding semaglutide (5.3%) at higher survodutide doses.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Survodutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.